Franklin Resources
SMMT icon

Franklin Resources’s Summit Therapeutics SMMT Stock Holding History

Franklin Resources’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-139,146
Closed -$2.96M – 3243
2025
Q2 		$2.96M Buy
139,146
+41,756
+43% +$952K ﹤0.01% 1567
2025
Q1 		$1.88M Sell
97,390
-63,689
-40% -$1.28M ﹤0.01% 1714
2024
Q4 		$2.87M Buy
161,079
+57,803
+56% +$1.12M ﹤0.01% 1594
2024
Q3 		$2.09M Buy
+103,276
New +$1.44M ﹤0.01% 1735

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
ACL
APEIRON Capital Ltd Hong Kong $107M AUM 9.59% 1-Year Est. Return

Franklin Resources's SMMT Position: Q3 2025 in Review

Franklin Resources sold out of Summit Therapeutics (SMMT) in Q3 2025, closing a stake of 139,146 shares — an estimated $2.96M sold.

Franklin Resources first reported a position in SMMT in Q3 2024 and held it in 4 quarters. The position peaked at $2.96M in Q2 2025. 232 funds tracked by Wall St. Rank hold SMMT as of Q3 2025.

  • Franklin Resources reported no remaining Summit Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Franklin Resources sold 139,146 Summit Therapeutics shares in Q3 2025, an estimated $2.96M.
  • Franklin Resources first reported a position in Summit Therapeutics in Q3 2024 and held it in 4 quarters.
  • Franklin Resources's Summit Therapeutics position peaked at $2.96M in Q2 2025.
  • 232 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2025.

Based on Franklin Resources's 13F filing for Q3 2025, filed 13 Nov 2025.